Male androgenetic alopecia aged 18-60 years Male androgenetic alopecia, finasteride, dutasteride, videodermoscope
Conditions
Interventions
oral finasteride 1 mg once daily in combination with oral dutasteride 0.5 mg once weekly,oral finasteride 1 mg once daily in combination placebo once weekly
Experimental Drug,Placebo Comparator Drug
Sponsors
Faculty of Medicine, Srinakharinwirot University
Eligibility
Sex/Gender
Male
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1.Male androgenetic alopecia aged 18 years or older. 2.Norwood-Hamilton classification type III vertex to V 3.Having received oral finasteride at least 1 mg daily for a minimum of 6 months, with evidence of disease stabilization
Exclusion criteria
Exclusion criteria: 1. Underlying diseases of hepatitis, kidney disease, cardiovascular disease 2. Family history of breast cancer or prostate cancer in first-degree relatives 3. History of depression, or suicidal idea 4. On the treatment of androgenetic alopecia within 6 months 4. Drug allergy to 5 alpha reductase inhibitors
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| change from baseline of hair density 24 weeks hairs/cm2 | — |
Secondary
| Measure | Time frame |
|---|---|
| change from baseline of Hair Diameter 24 weeks micrometer,Global Photography Assessment by 2 Independent Dermatologists 24 weeks 7-point scales,Patient Satisfaction 24 weeks Visual Analogue Scales | — |
Countries
Thailand
Contacts
Public ContactSaranya Khunkhet
Department of Dermatology, Faculty of Medicine, Srinakharinwirot University
Outcome results
None listed